ClinicalTrials.gg
RecruitingNCT06997900MARCS 2Updated Jul 31, 2025

Menopur And Rekovelle Combination Study Version 2.0

A Phase 2 interventional study of Combination therapy : Follitropin delta and HP-hMG in IVF, Controlled Ovarian Simulation and Fertility Disorders, sponsored by Clinique Ovo. Recruiting at 2 sites in Canada. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Clinique Ovo · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is:

- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ?

Researchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes

Participants will:

  • Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight
  • Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels
  • Undergo standard IVF procedures including egg retrieval and embryo assessment
Read the detailed description

In vitro fertilization (IVF) is a multi-step process that includes controlled ovarian stimulation, oocyte retrieval, fertilization, and embryo transfer. Success in IVF largely depends on how the ovaries respond to stimulation using exogenous gonadotropins. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are key to folliculogenesis and oocyte maturation, and are central to ovarian stimulation protocols. Physicians typically determine the appropriate stimulation regimen by considering clinical factors such as age, body weight, and ovarian reserve, and choosing the type and dose of gonadotropins accordingly. The combined use of FSH and LH, such as in protocols incorporating both recombinant FSH and human menopausal gonadotropin (hMG), has shown improvements in ART outcomes.

Among gonadotropins, follitropin delta (REKOVELLE) is a recombinant FSH with allowing for individualized dosing based on anti-Müllerian hormone (AMH) levels and body weight. The ESTHER-1 trial demonstrated its safety and efficacy when personalized using this algorithm. Furthermore, the MARCS study showed that combining REKOVELLE with highly purified hMG (MENOPUR) led to higher number of retrieved oocytes and improved blastulation rate compared to REKOVELLE alone.

However, in some regions, AMH is not routinely used to personalize FSH dosing. Other trials, such as RITA-1 and RITA-2, demonstrated the potential of adjusting REKOVELLE doses based solely on age and body weight. Inspired by these findings, this study seeks to evaluate dosing based on age and weight for combination therapy with REKOVELLE and MENOPUR.

This is a prospective, interventional, phase II clinical trial enrolling 200 participants across two fertility centers in Canada. The objective is to determine whether individualizing the starting doses of REKOVELLE and MENOPUR based on age and body weight results in similar clinical outcomes to those achieved when dosing is based on AMH and weight, as per the standard REKOVELLE dosing algorithm.

Unlike the original MARCS protocol, which used a fixed dose of REKOVELLE and variable MENOPUR, this study will apply an adjustable REKOVELLE dose and a fixed MENOPUR dose. The study aims to assess ovarian response, blastulation, embryo quality, pregnancy rates, and safety outcomes, particularly the risk of ovarian hyperstimulation syndrome (OHSS).

This research will contribute valuable data on the feasibility and effectiveness of an age- and weight-based dosing regimen for REKOVELLE and MENOPUR mixed protocol ovarian stimulation, especially in clinical environments where AMH measurement is less accessible.

02

Conditions studied

  • IVF
  • Controlled Ovarian Simulation
  • Fertility Disorders
03

In context

Lead sponsor

Clinique Ovo is the lead sponsor of 36 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 40 years inclusively at the time of consent form signature
  • Diagnosis of unexplained infertility, tubal infertility, endometriosis stage I/II or male factor infertility
  • Regular menstrual cycles of 24-35 days
  • Presence of both ovaries
  • Early follicular phase FSH serum concentration \<10 IU/L measured between Day 2 and Day 5 of menstrual cycle within the previous 24 months
  • First IVF/ICSI cycle
  • IVF antagonist protocol prescribed
  • Partner or donor ejaculated sperm (fresh or frozen) used for fertilization

Exclusion criteria

Exclusion Criteria:

  • Women undergoing oocyte donation
  • Endometriosis stage III/IV
  • High risk of OHSS (AMH ≥ 35 pmol/L)
  • (BMI) > 40 kg/m2 Protocol number: IIS-1056 MARCS 2.0 Study Version: 1.1 - Date : 14 APR 2025 Page 12 of 28
  • Gynaecological haemorrhages of unknown aetiology
  • History of recurrent miscarriages defined as ≥ 3 consecutive losses
  • Renal or hepatic impairment
  • to any active ingredient or in follitropin delta and/or HP-hMG
  • Tumours of hypothalamus or pituitary gland
  • Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome
  • Current or history of ovarian, uterine or mammary carcinoma
  • History of thrombophilia
  • Use of hormonal preparations (except for 17β-estradiol, testosterone gel, DHEA and thyroid medication) during the last menstrual cycle
  • Women participating in any other interventional research project
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Follitropin delta and HP-hMG

    Drug: Combination therapy : Follitropin delta and HP-hMG

Interventions

  • DrugCombination therapy : Follitropin delta and HP-hMG

    Drug page: Follitropin delta

    Follitropin delta dose will be determined by age. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight.

06

What researchers measure

Primary outcomes

  1. number of good quality (>3BB) or utilizable blastocysts per treatment cycle at day 5 or 6 of embryo culture

    Time frame: 5 to 6 days after egg retrieval (up to 1 to 2 months after enrollment)

Secondary outcomes

  1. Safety profile of follitropin delta + HP-hMG mixed protocol

    Patient rate that will develop ovarian hyperstimulation syndrome (OHSS)

    Time frame: up to 15 days after egg retrieval

07

Study locations

2 of 2 sites recruiting
  • Ottawa fertility centre
    Ottawa, Ontario, Canada
    Recruiting
    • Jenna Gale, MD · Principal investigator
  • Clinique ovo
    Montreal, Quebec H4P 2S4, Canada
    Recruiting
    • Isaac-Jacques Kadoch, MD · Principal investigator
08

References and documents

Publications

  • Bissonnette F, Minano Masip J, Kadoch IJ, Librach C, Sampalis J, Yuzpe A. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil Steril. 2021 Apr;115(4):991-1000. doi: 10.1016/j.fertnstert.2020.09.158. Epub 2020 Nov 30. PubMed 33267959 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Aug 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 31, 2025
StartActual
Jul 4, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2027
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06997900
Lead sponsor
Clinique Ovo
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jul 4, 2025
Primary completion
Aug 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 31, 2025

Study contacts

Marya Far
Contact
m.far@cliniqueovo.com
514-798-2000 ext. 759

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion